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Background: Percutaneous repair of periprosthetic paravalvular leak (PVL) is
emerging as a potential therapy in patients that are at high surgical risk. We report our
outcomes with this procedure in patients referred for catheter based repair of peri-
prosthetic paravalvular regurgitation.
Methods: We retrospectively identiﬁed 43 percutaneous PVL closures in 40 patients
performed at our institution between May 2009 and November 2012.
Results: The mean age of patients undergoing percutaneous PVL closure was 70
years, with 98% of patients in NYHA class III or IV heart failure and 63% of patients
having evidence of hemolytic anemia. There was a signiﬁcant burden of co-morbid-
ities with a mean estimated mortality of 10.2% as predicted by the STS score. Majority
(86%) were mitral PVL closures. In 81% of cases antegrade transseptal approach was
used. General anesthesia was used sparingly (4 cases). In 50% of cases, more than 1
device was needed. Amplatzer Vascular Plug II was the most frequently used device.
Percutaneous PVL closure was successful in 91% of patients with residual regurgi-
tation of grade 1+ in 51% patients and 2+ in 95% of patients. Procedural failure
occurred in 4 cases.Reasons for failure included prosthetic valve impingement, failure
to cross the leak and signiﬁcant residual leak despite device. Thirty day mortality was
7.5% (3 patients). A total of 3 patients had surgical valve replacement following
percutaneous PVL closure; of which 2 patients underwent surgery within 30 days
and one patient had surgery after 1.6 years. At a mean follow up of 208 days (range 1-
888 days), all cause mortality was 30%.
Conclusions: Percutaneous PVL closure is a valuable treatment option in patients
with paraprosthetic paravalvular regurgitation at high surgical risk, with good acute
procedural success rates.
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Background: Mitral balloon valvuloplasty (MBV) with single balloon (MBVSB) is
the less expensive technique to perform MBV. The objectives were to evaluate long-
term follow-up (FU) of MBVSB Balt and to determine independent predictors of
survival and event-free survival (EFS).
Methods: From 1987 to 12-31-2013, 526 procedures of MBV were performed,
404 (76.8%) with MBVSB Balt, being 256 procedures with long-term FU. The
balloon diameter was 25 mm in 5 procedures and 30 mm in 251, mean dilatation area
7.020.30 cm2. The FU was 5533 (1 to 198) months. To determine independent
predictors of survival and EFS it was used the multivariate Cox analysis.
Results: Mean age was 38.012.6 (13 to 83) years, being 222 (86.7%) female, 215
(84.0%) in sinus rhythm, echo score (ES) 7.21.5 (4 to 14) points and echo mitral
valve area (MVA) pre-MBVSB 0.930.21 cm2. Mean pre and post-MBV area
(Gorlin) was 0.900.20 and 2.020.37 cm2 (p< 0.001) and success MVA 1,5 cm2
in 241 (94.1%) procedures and mean pulmonary artery pressure pre and post MBV
were 2710 and 207 mmHg. Three (1.2%) patients began the FU with severe mitral
regurgitation (SMR). At the end of the FU 118 (46.1%) patients were in NYHA FC I,
71 (27.7%) in FC II, 53 (20.7%) in FC III, 3 (1.2%) in FC IV and there were 11 deaths
(4.3%), 9 (3,5%) were cardiac death, being 5 during cardiac surgery. There were
17 (8.2%) patients with new SMR at the end of the FU. Twelve (4.7%) patients were
submitted to new MBV, 27 (10.5%) to mitral valve surgery and 70 (26.3%) patients
used no medication at the end of the FU. Independent predictors of survival with
7 variables were: ES 8 (P< 0.002, HR¼0.143), age 50 years old (P¼0.014, HR
0.202) and absence of mitral valve surgery in the FU (P¼0.004, HR 0.170), being
cardiac surgery in fhe FU the 7th variable and with 6 variables independent predictors
were: EE 8 (p< 0.001, HR 0,116) and age 50 years old (P¼0,011, HR¼0,203).
Independent predictors of EFS were: absence of prior comissurotomy (P< 0.002,
HR 0.318), female (P¼0.036, HR 0.466) and MVA post MBV.
Conclusions: MBVSB Balt was efﬁcient with durable results similar to others tech-
niques being less expensive.
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Background: Many patients with severe symptomatic native mitral valve regurgita-
tion are not candidates for surgical replacement or repair due to high operative risk.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/ValvulWhile percutaneous repair therapies such as MitraClip are a viable option for such
patients, many have unfavorable anatomy that precludes treatment. Transcatheter
mitral valve implantation (TMVI) is a novel treatment option. We describe the ﬁrst
in human implantation of the CardiAQ valve via transapical approach.
Methods: An 88-year-old female patient with severe mitral regurgitation secondary to
A1/A2 leaﬂet ﬂail and refractory NYHA class IIIb dyspnoea was referred for treat-
ment. Co-morbidities included prior coronary artery bypass surgery and renal failure.
Left ventricular systolic function was preserved. Following discussion in our heart
team meeting the patient was declined surgery and deemed unsuitable for MitraClip.
TMVI was performed under compassionate use provision.
Results: The 33Fr CardiAQ delivery system was inserted via transapical approach in
the hybrid operating theatre. Using transoesophageal echocardiography guidance,
successful device implantation was achieved with an accurate and stable prosthesis
position and immediate elimination of the mitral regurgitation with only trace para-
valvular leak. Over a follow up period of 1 week the prosthetic valve remained well
functioning as assessed by sequential echocardiography, the patient experienced
signiﬁcant symptomatic improvement and recovery was uneventful.
Conclusions: Our initial experience with transcatheter mitral valve implantation using
the CardiAQ device via transapical approach highlights the feasibility and effective-
ness of this promising therapy in treating severe mitral regurgitation.
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Background: Transcatheter mitral valve implantation is an emerging therapeutic
option for high-risk patients with severe symptomatic mitral regurgitation. The Tiara
is a catheter-based self-expanding mitral bio-prosthesis, speciﬁcally designed to ﬁt the
complex anatomical structure of the mitral apparatus. It is implanted using a trans-
apical approach.. Because transesophageal echocardiography (TEE) provides superb
imaging of the mitral valve in both 2 and 3-D, and has the ability to provide real time
information, TEE is ideally suited both assessing suitability and guiding the implan-
tation of trans-catheter mitral procedures. We describe here the TEE guidance of the
ﬁrst 2 human implantations of the Tiara.
Methods: The ﬁrst 2 cases of Transapical Mitral Valve Implantation (TAMI) of
the Tiara were performed in a 72 year-old male and a 60 years old woman with
severe functional MR. Anatomical suitability for Tiara implantation was conﬁrmed
by transthoracic echo, TEE and CT angiographic assessment prior to implantation.
Implantation was guided by both TEE and ﬂuoroscopy. TEE was critical in deter-
mining the orientation of the “D” shaped Tiara prior to deployment. In particular,
the orientation of the device in the left atrium was conﬁrmed using X-plane
imaging, and rotational orientation by real time 3-D echo. Final deployment position,
paravalvular mitral regurgitation and the presence of any complications was evaluated.
Results: TEE guided Tiara implantation was completed successfully in both patients
and both valves were deployed in an appropriate position and orientation. There were
no complications detected by TEE at the time of implantation. Speciﬁcally no left
ventricular outﬂow tract obstruction, pericardial effusion or deterioration in LV or RV
function was noted. No new wall motion abnormalities were noted. Mitral regurgi-
tation was reduced from 4+ to trivial and trans-mitral gradient was minimal in both
patients.
Conclusions: TEE echo provides critical real time information that is integral to
successful positioning, deployment and assessment of outcomes with trans-catheter
mitral valve implantation.
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Background: To compare the immediate and 18-month clinical and echocardio-
graphic outcome of Inoue and multi-track system for balloon mitral valvuloplasty
(BMV).
Methods: We included 78 consecutive patients with moderate to severe rheumatic
mitral stenosis (MS) [mitral valve area (MVA)< 1.5 cm2] and clinically indicated
BMV. The ﬁrst 42 consecutive patients were assigned to Inoue BMV (group I), and
the following 36 consecutive patients were assigned to multi-track system (group M).
Clinical and echocardiographic assessment was performed before, immediately after,
3 months after, and 18 months after the procedure.
Results: The successful immediate result [MVA > 1.5 cm2 and mitral regurgitation
(MR) < II/IV] was achieved in 40 (95.23%) patients of group I and 34 (94.44%)
patients of group M (P ¼ 0.12). Immediately after BMV,MVA increased from
0.9  0.4 to 1.7  0.5 cm2 in group I and from 0.8  0.2 to 1.9  0.3 cm2 in group M
(P < 0.01). Bilateral commissural splitting was signiﬁcantly higher in group M
(P < 0.01). This was associated with higher incidence of mild commissural mitral
regurgitation. There were no signiﬁcant differences of moderate to severe MR. Both
procedure and ﬂuoroscopy time were signiﬁcantly shorter in group I (P < 0.001).
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